Table 3.
The severity and frequency of CINV in HCC patients after TACE or HAIC
| (A) Number of CINV patients by treatment groups | |||
|---|---|---|---|
| Acute CINV | Delayed CINV | Both CINV | |
| Patients without NK1 antagonist (n = 40) | 18 (45.0%) | 11 (27.5%) | 9 (22.5%) |
| Patients with NK1 antagonist (n = 97) | 3 (3.1%) | 5 (5.1%) | 2 (2.0%) |
| (B) Number and severity of adverse events in patients by treatment groups | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nausea (n = 20) |
Vomiting (n = 14) |
Anorexia (n = 22) |
||||||
| Grade 1 | Grade 2 | Grade 1 | Grade 2 | Grade 1 | Grade 2 | |||
| Patients without NK1 antagonists | 10 | 6 | 11 | 3 | 9 | 7 | ||
| Patients with NK1 antagonists | 3 | 1 | 0 | 0 | 4 | 2 | ||
| (C) Number and severity of adverse events in CINV patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nausea (n = 20) |
Vomiting (n = 14) |
Anorexia (n = 22) |
||||||
| Grade 1 | Grade 2 | Grade 1 | Grade 2 | Grade 1 | Grade 2 | |||
| Acute CINV only (n = 10) | 5 | 2 | 6 | 2 | 4 | 3 | ||
| Delayed CINV only (n = 5) | 3 | 0 | 0 | 0 | 2 | 2 | ||
| Both CINV (n = 11) | 5 | 5 | 5 | 1 | 7 | 4 | ||